Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers.

According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person said Pfizer has approached the company about a deal that could value it at as much as €1.5 billion”. No information are suggesting that other parties are also in the sale talks with Cellectis.

Pfizer and Cellectis declined to comment this rumor but of course, the market reacts immediately with a 14% increase of Cellectis’ shares.


Last March, the French company, raised €200 million on the New York’s NASDAQ stock market, to continue the development of its CAR-T therapy, one of the hottest Biotech areas right now.

Cellectis intends to reprogrammed T-cells to make your own body immunized against cancer cells. To do so, the company harvests T-cells from third-party patients and re-inject them after reprogramming. In contrast, its main competitors Novartis, Juno, Bluebird and Kite, are taking patient’s own T-cells.

Entering NASDAQ, was a way for Cellectis to be judged by the same yardstick as the others. The company’s shares who jump up to 200% this year, are giving the company a market value of €1.3 billion. The company’s lead candidate, a Servier-partnered treatment for leukemia, is slated to enter the clinic this year.

Pfizer already owns around 10% of Cellectis after they entered a €2.6 billion partnership to develop CAR-T therapies together. An acquisition of Cellectis would strengthen Pfizer’s intention to become a major player in the CAR-T race and close the gap with US Merck, BMS, AstraZeneca and others.

Let's Continue The Conversation

Feel free to send us comments about this article to and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.